Gene–environment interactions for complex traits: definitions, methodological requirements and challenges

Genetic and environmental risk factors and their interactions contribute to the development of complex diseases. In this review, we discuss methodological issues involved in investigating gene–environment (G × E) interactions in genetic–epidemiological studies of complex diseases and their potential relevance for clinical application. Although there are some important examples of interactions and applications, the widespread use of the knowledge about G × E interaction for targeted intervention or personalized treatment (pharmacogenetics) is still beyond current means. This is due to the fact that convincing evidence and high predictive or discriminative power are necessary conditions for usefulness in clinical practice. We attempt to clarify conceptual differences of the term ‘interaction’ in the statistical and biological sciences, since precise definitions are important for the interpretation of results. We argue that the investigation of G × E interactions is more rewarding for the detailed characterization of identified disease genes (ie at advanced stages of genetic research) and the stratified analysis of environmental effects by genotype or vice versa. Advantages and disadvantages of different epidemiological study designs are given and sample size requirements are exemplified. These issues as well as a critical appraisal of common methodological concerns are finally discussed.

[1]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[2]  N E Day,et al.  European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.

[3]  M. Caldwell,et al.  A prospective, randomized pilot trial of model-based warfarin dose initiation using CYP2C9 genotype and clinical data. , 2005, Clinical medicine & research.

[4]  J. Rees,et al.  The genetics of sun sensitivity in humans. , 2004, American journal of human genetics.

[5]  M. Levin,et al.  Genetic susceptibility to infectious diseases. , 2003, The Pediatric Infectious Disease Journal.

[6]  M. Plebanski,et al.  Malaria parasite interactions with the human host. , 2004, Journal of postgraduate medicine.

[7]  D. Altshuler,et al.  The multiethnic cohort study: exploring genes, lifestyle and cancer risk , 2004, Nature Reviews Cancer.

[8]  J. Beckmann,et al.  Trick or treat: The effect of placebo on the power of pharmacogenetic association studies , 2005, Human Genomics.

[9]  Testing linkage and Gene × Environment interaction: Comparison of different affected sib‐pair methods , 2003, Genetic epidemiology.

[10]  M J Khoury,et al.  Evolving methods in genetic epidemiology. III. Gene-environment interaction in epidemiologic research. , 1997, Epidemiologic reviews.

[11]  W James Gauderman,et al.  Sample size requirements for matched case‐control studies of gene–environment interaction , 2002, Statistics in medicine.

[12]  J. Blackwell,et al.  Genetics and genomics in infectious disease susceptibility. , 2001, Trends in molecular medicine.

[13]  D. Hunter Gene–environment interactions in human diseases , 2005, Nature Reviews Genetics.

[14]  J M Robins,et al.  Differential misclassification and the assessment of gene-environment interactions in case-control studies. , 1998, American journal of epidemiology.

[15]  Artemis P. Simopoulos,et al.  Nutrigenetics and nutrigenomics , 2004 .

[16]  Paolo Vineis,et al.  A self-fulfilling prophecy: are we underestimating the role of the environment in gene-environment interaction research? , 2004, International journal of epidemiology.

[17]  P. Brown,et al.  Iatrogenic Creutzfeldt‐Jakob disease , 1994, Neurology.

[18]  A. N. Pettitt,et al.  One Degree of Freedom for Nonadditivity: Applications with Generalized Linear Models and Link Functions , 1989 .

[19]  D J Schaid,et al.  Potential misinterpretation of the case-only study to assess gene-environment interaction. , 1999, American journal of epidemiology.

[20]  D. Spiegelman,et al.  Power and sample size calculations for case-control studies of gene-environment interactions with a polytomous exposure variable. , 1997, American journal of epidemiology.

[21]  C R Weinberg,et al.  Designing and analysing case-control studies to exploit independence of genotype and exposure. , 1997, Statistics in medicine.

[22]  G. Rose Sick individuals and sick populations. , 2001, International journal of epidemiology.

[23]  L. C. Stene Study of genes and environmental factors in complex diseases , 2002, The Lancet.

[24]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[25]  Howard L McLeod,et al.  Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype , 2005, Thrombosis and Haemostasis.

[26]  D. Thomas,et al.  The role of interacting determinants in the localization of genes. , 2001, Advances in genetics.

[27]  J. Witte,et al.  Family-based association studies. , 1999, Journal of the National Cancer Institute. Monographs.

[28]  Peter Kraft,et al.  Exploiting Gene-Environment Interaction to Detect Genetic Associations , 2007, Human Heredity.

[29]  J H Lubin,et al.  Power and sample size calculations in case-control studies of gene-environment interactions: comments on different approaches. , 1999, American journal of epidemiology.

[30]  Allen D. Roses,et al.  Pharmacogenetics and drug development: the path to safer and more effective drugs , 2004, Nature Reviews Genetics.

[31]  R. Judson Using Multiple Drug Exposure Levels to Optimize Power in Pharmacogenetic Trials , 2003, Journal of clinical pharmacology.

[32]  D. Rao,et al.  An epidemiologic approach to gene‐environment interaction , 1990, Genetic epidemiology.

[33]  David Clayton,et al.  Epidemiological methods for studying genes and environmental factors in complex diseases , 2001, The Lancet.

[34]  D J Schaid,et al.  Case‐parents design for gene‐environment interaction , 1999, Genetic epidemiology.

[35]  L. Abel,et al.  Genetic epidemiology of infectious diseases in humans: design of population-based studies. , 1998, Emerging infectious diseases.

[36]  David B. Goldstein,et al.  Pharmacogenetics goes genomic , 2003, Nature Reviews Genetics.

[37]  Raymond J Carroll,et al.  Exploiting gene‐environment independence in family‐based case‐control studies: Increased power for detecting associations, interactions and joint effects , 2005, Genetic epidemiology.

[38]  R C Elston,et al.  The study of candidate genes in drug trials: sample size considerations. , 1999, Statistics in medicine.

[39]  Sample Size Calculations for Main Effects and Interactions in Case–control Studies using Stata's nchi2 and npnchi2 Functions , 2003 .

[40]  Walter C Willett,et al.  Balancing Life-Style and Genomics Research for Disease Prevention , 2002, Science.

[41]  Stephen G Ryan Regression to the truth: replication of association in pharmacogenetic studies. , 2003, Pharmacogenomics.

[42]  Andrew G Rundle,et al.  Further development of the case-only design for assessing gene-environment interaction: evaluation of and adjustment for bias. , 2004, International journal of epidemiology.

[43]  W D Flanders,et al.  Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! , 1996, American journal of epidemiology.

[44]  Nigel Stallard,et al.  Statistical design and analysis of pharmacogenetic trials , 2005, Statistics in medicine.

[45]  H. Cordell Epistasis: what it means, what it doesn't mean, and statistical methods to detect it in humans. , 2002, Human molecular genetics.

[46]  W. Thompson,et al.  Effect modification and the limits of biological inference from epidemiologic data. , 1991, Journal of clinical epidemiology.

[47]  Jenny Chang-Claude,et al.  Sample size requirements for indirect association studies of gene–environment interactions (G × E) , 2008, Genetic epidemiology.

[48]  J J Goedert,et al.  Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. , 1997, Science.

[49]  M. Fallin,et al.  Genetic dissection methods: designs used for tests of gene-environment interaction. , 2004, Current opinion in genetics & development.

[50]  E. Begg,et al.  Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? , 2005, Pharmacogenetics and genomics.

[51]  R C Elston,et al.  Testing drug response in the presence of genetic information: sampling issues for clinical trials. , 2000, Pharmacogenetics.

[52]  N E Day,et al.  Sample size determination for studies of gene-environment interaction. , 2001, International journal of epidemiology.

[53]  J. Witte,et al.  Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. , 1999, American journal of epidemiology.

[54]  J. Wittes,et al.  Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. , 1991, JAMA.

[55]  P. Brennan,et al.  Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? , 2002, Carcinogenesis.